Home Investment Portfolio Receptor-OncoTek Innovation Type: Therapeutics Cancer Type: Other Funding Stage: Proof of Concept Fund: Compass Rose Preclinical development of PoLi-PTX, Intraperitoneal ovarian cancer therapy Related news There are currently no news items related to this portfolio company. CONNECT WITH FACIT Learn more about how we are driving made-in-Ontario oncology innovations reach the market. Please note that only Ontario-based innovations related to oncology and cancer care are eligible for FACIT's investment and commercialization support. Name: Email: Message:
